LEO Pharma names a new member to its global leadership team

23 September 2020

Privately-held Danish medical dermatology specialist LEO Pharma today said that Becki Morison will join the company, effective October 1 in the position of executive vice president, global therapeutics and value strategy.

Ms Morison succeeds Patrice Baudry, who will take over responsibility for establishing LEO Pharma’s rare disease presence.

Most recently Ms Morison was VP, US Immunology, at US pharma major Eli Lilly (NYSE: LLY). Prior to that, she held several leadership positions in the US, Australia as well as in the UK and the Nordics. In addition to her international experience, she has a proven track record in building and growing innovative pharmaceutical franchises in different therapeutic areas including orphan diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK